|
Affiliation |
Faculty of Medicine School of Medicine Department of Hemovascular Medicine and Artificial Organs |
|
Title |
Professor |
|
External Link |
|
TSURUDA Toshihiro
|
|
|
Degree 【 display / non-display 】
-
博士（医学） ( 2000.3 宮崎医科大学 )
-
学士（医学） ( 1992.3 宮崎医科大学 )
Papers 【 display / non-display 】
-
Nitroglycerin use and adverse clinical outcomes in elderly patients with acute coronary syndrome Reviewed
Komaki S., Matsuura Y., Tanaka H., Moribayashi K., Yamamura Y., Kurogi K., Ideguchi T., Yamamoto N., Nakai M., Tsuruda T., Kaikita K.
Open Heart 11 ( 1 ) 2024.1
Language：English Publishing type：Research paper (scientific journal) Publisher：Open Heart
Objective The primary care for acute coronary syndrome (ACS) includes the administration of nitroglycerin (GTN). This study aimed to investigate the association between the use of GTN before percutaneous coronary intervention (PCI) for ACS and clinical outcomes. Methods Nine-hundred and forty-seven patients who underwent PCI for ACS were examined and classified into two groups: those who were treated with GTN before PCI (GTN group) and those who were not (non-GTN group). The incidence of major adverse cardiovascular events (MACE), which consist of all-cause mortality, non-fatal myocardial infarction, stroke and rehospitalisation for heart failure at 1 year, was compared between the two groups. Results This study identified 289 patients with ACS who used GTN preceding PCI. Pre-PCI systolic blood pressure was significantly lower in the GTN group than in the non-GTN group (median (IQR); 132.0 (110.0-143.5) mm Hg vs 134.0 (112.0-157.0) mm Hg, respectively, p=0.03). Multivariate Cox regression analysis indicated that GTN use preceding PCI showed an independent association with the incidence of MACE (HR 1.57; 95% CI 1.09-2.28; p=0.016). Overall, the incidence of MACE 1 year after PCI for ACS was significantly higher in the GTN group than in the non-GTN group (log-rank test, p=0.024); however, this trend was consistently found in elderly patients aged ≥75 years (p=0.002) but not in non-elderly patients aged <75 years (p=0.773). Conclusions GTN use preceding PCI for ACS is associated with lower blood pressure and adverse clinical outcomes in elderly patients.
-
Tsuruda T., Funamoto T., Suzuki C., Yamamura Y., Nakai M., Chosa E., Kaikita K.
Archives of Osteoporosis 18 ( 1 ) 129 2023.12
Authorship：Lead author, Corresponding author Language：English Publishing type：Research paper (scientific journal) Publisher：Archives of Osteoporosis
Purpose: The purpose of this study was to investigate the morphological characteristics of the aortic valve and identify factors associated with the progression of aortic valve stenosis (AS) in osteoporosis patients. Methods: In this single-center prospective cohort study, we recruited 10 patients (mean age: 75 ± 7 years, 90% female) who were taking anti-resorptive medicines at the outpatient clinic of University of Miyazaki Hospital, Japan. Baseline assessments, including transthoracic echocardiogram, blood sampling, and dual energy X-ray absorptiometry, were performed. Follow-up assessments were conducted at 6, 12, 18, and 24 months. Results: During the 2-year follow-up, three patients with aortic valve peak flow velocity (AV PFV) ≥2 m/s at baseline developed moderate AS, which is defined as AV PFV ≥3 m/s. However, seven patients with AV PFV <2 m/s did not exhibit any progression of AS. There were significant variations in terms of bone mineral density, T-score values, and biomarkers associated with bone turnover (i.e., bone alkaline phosphatase, tartrate-resistance acid phosphatase-5b) among the enrolled patients, but none of these factors were found to be associated with the progression of AS. All patients exhibited low vitamin D status, with a median level of 16.1 ng/mL (25th percentile, 9.7 ng/mL; 75th percentile, 23 ng/mL). The baseline levels of AV PFV values were negatively correlated with 25-hydroxyvitamin D levels, determined by univariate linear regression analysis (beta coefficient = -0.756, 95% confidence interval, -0.136 ̶ -0.023, p = 0.011). Conclusion: Our data suggest that low vitamin D status might be a potential risk factor for the progression of AS in osteoporosis patients undergoing treatment with anti-resorptive medicines. Summary : Elderly patients with osteoporosis patients exhibited a subset of aortic valve stenosis. Our data suggest that the baseline aortic valve peak flow velocity predicts the progression of aortic valve stenosis, and there might be an association between the progression and the co-existing low vitamin D status in these patients.
-
Natriuretic peptides potentiate cardiac hypertrophic response to noradrenaline in rats Reviewed
Jiang D., Matsuzaki M., Ida T., Kitamura K., Tsuruda T., Kaikita K., Kato J.
Peptides 166 171035 2023.8
Language：English Publishing type：Research paper (scientific journal) Publisher：Peptides
Excessive activation of the sympathetic nervous system is involved in cardiovascular damage including cardiac hypertrophy. Natriuretic peptides are assumed to exert protective actions for the heart, alleviating hypertrophy and/or fibrosis of the myocardium. In contrast to this assumption, we show in the present study that both atrial and C-type natriuretic peptides (ANP and CNP) potentiate cardiac hypertrophic response to noradrenaline (NA) in rats. Nine-week-old male Wistar rats were continuously infused with subcutaneous 30 micro-g/h NA without or with persistent intravenous administration of either 1.0 micro-g/h ANP or CNP for 14 days. Blood pressure (BP) was recorded under an unrestrained condition by a radiotelemetry system. Cardiac hypertrophic response to NA was evaluated by heart weight/body weight (HW/BW) ratio and microscopic measurement of myocyte size of the left ventricle. Mean BP levels at the light and dark cycles rose by about 20 mmHg following NA infusion for 14 days, with slight increases in HW/BW ratio and ventricular myocyte size. Infusions of ANP and CNP had no significant effects on mean BP in NA-infused rats, while two natriuretic peptides potentiated cardiac hypertrophic response to NA. Cardiac hypertrophy induced by co-administration of NA and ANP was attenuated by treatment with prazosin or atenolol. In summary, both ANP and CNP potentiated cardiac hypertrophic effect of continuously infused NA in rats, suggesting a possible pro-hypertrophic action of natriuretic peptides on the heart.
-
Komaki S., Ishii M., Kaichi R., Takae M., Mori T., Toida R., Kurogi K., Matsuura Y., Yamamoto N., Tsujita K., Tsuruda T., Kaikita K.
Heart and Vessels 38 ( 7 ) 919 - 928 2023.7
Language：English Publishing type：Research paper (scientific journal) Publisher：Heart and Vessels
The relationship between coronary artery calcium (CAC) and bleeding events after percutaneous coronary intervention (PCI) in patients with chronic coronary syndrome (CCS) is not well established. This study aimed to examine the association between CAC scores and clinical outcomes after PCI in patients with CCS. This retrospective observational study included 295 consecutive patients who underwent multidetector computer tomography and were scheduled for their first elective PCI. Patients were categorized into two groups based on the CAC scores (low: ≤ 400 or high: > 400). The bleeding risk was evaluated using the Academic Research Consortium for High Bleeding Risk (ARC-HBR) criteria. The primary clinical outcome was a major bleeding event within 1 year after PCI, defined as Bleeding Academic Research Consortium (BARC) 3 or 5. The high CAC score group had a higher proportion of patients meeting the ARC-HBR criteria than the low CAC score group (52.7% vs. 31.3%, p < 0.001). Kaplan–Meier survival analysis showed that the incidence of major bleeding events was higher in the high CAC score group as compared to the low CAC score group (p < 0.001). Furthermore, multivariate Cox regression anal ysis revealed that a high CAC score was an independent determinant of major bleeding events during the first year after PCI. A high CAC score is significantly associated with the incidence of major bleeding events after PCI in CCS patients.
-
Jiang D, Matsuzaki M, Kawagoe Y, Kitamura K, Tsuruda T, Kaikita K, Asada Y, Kato J
Journal of the renin-angiotensin-aldosterone system : JRAAS 2023 4201342 2023
Language：English Publishing type：Research paper (scientific journal) Publisher：Journal of the renin-angiotensin-aldosterone system : JRAAS
Objective: We reported that rats infused with angiotensin II (Ang II) are not only a model of hypertension but also of augmented 24 h blood pressure variability (BPV). In this study, we examined the mechanisms for Ang II-induced BPV, focusing on BP, heart rate (HR), baroreceptor reflex sensitivity (BRS), and medial area of the aortic arch. Methods: Nine-week-old male Wistar rats were infused with subcutaneous 5.2 μg/kg/h Ang II with or without oral administration with 30 mg/kg/day azelnidipine for 14 days. BP and HR were recorded every 15 min under an unrestrained condition by a radiotelemetry system, while BPV was evaluated by standard deviation of BP. BRS was quantified by a sequence analysis, and medial thickness of the aortic arch was measured by microscopic examination. Results: BPV increased at days 7 and 14 following continuous infusion of Ang II. Before the infusion, a positive correlation was found between BP and HR, but it became negative at day 7 and then weakened or disappeared at day 14. BRS was slightly impaired at day 7 and significantly lowered at day 14, a phenomenon accompanied by thickened medial area of the aortic arch in Ang II-infused rats. Those Ang II-induced alterations were all significantly attenuated by azelnidipine. Conclusions: The present findings suggest sequential changes in the mechanisms behind augmented BPV in rats continuously infused with Ang II over 14 days.
DOI： 10.1155/2023/4201342
Books 【 display / non-display 】
-
バイスタンダーCPRの生命・機能予後に関する横断研究－宮崎市消防局管内で発生した心肺機能停止1,686年の解析－
鶴田敏博、濱畑貴晃、遠藤穣治、海北幸一（ Role： Joint author）
宮崎県医師会 2023.10
Language：Japanese Book type：Scholarly book
-
人々を繋ぎ、宮崎県から世界へ～これからの東九州メディカルバレー構想と宮崎大学の医工連携事業 Reviewed
鶴田敏博、平山麻美、小牧聡一、中村小夜子、宮田敬公、金子彰彦、福永千紗、岩本脩成、森田 徹、荒武 尚（ Role： Joint author）
宮崎県医師会 2023.3
Responsible for pages：112-116 Language：Japanese Book type：Scholarly book
-
宮崎大学学生の医療機器開発への関心についての調査
平山麻美、鶴田敏博、小牧聡一、中村小夜子、宮田敬公、金子彰彦、福永千紗、岩本脩成、森田 徹、荒武 尚（ Role： Joint author）
宮崎県医師会 2023.3
Language：Japanese Book type：Scholarly book
-
腎保護薬update 可溶性グアニル酸シクラーゼ刺激薬
鶴田敏博（ Role： Sole author）
東京医学社 2021.8
Language：Japanese Book type：Scholarly book
-
Current Therapy in Cardiovascular Diseases
（ Role： Joint author）
2020.1
Total pages：3 Responsible for pages：295-297 Language：Japanese Book type：Scholarly book
MISC 【 display / non-display 】
-
心不全の基礎研究．心不全の分子機序．神経体液性因子．アドレノメデュリン Invited
鶴田敏博、北村和雄
日本臨床社 76 ( 9 ) 136 - 143 2018
Language：Japanese Publishing type：Article, review, commentary, editorial, etc. (scientific journal)
-
骨と心血管を巡る破骨細胞形成抑制因子、「オステオプロテゲリン」 Invited
鶴田敏博、宇田川信之、北村和雄
循環制御 39 ( 3 ) 157 - 159 2018
Language：Japanese Publishing type：Article, review, commentary, editorial, etc. (scientific journal) Publisher：日本循環制御学会
-
What are the clinical consequences of hyperkalemia on the heart and what are the uses of electrocardiograms in hyperkalemia?
Ideguchi T, Tsuruda T
E-journal of Cardiology Practice 14 12 2016.6
Language：English Publishing type：Research paper, summary (national, other academic conference) Publisher：European society of cardiology
-
Guanylate cyclase on renal protection; update
Tsuruda T, Kitamura K
Kidney and Dialysis 80 ( 4 ) 556 - 560 2016.4
Language：Japanese Publishing type：Article, review, commentary, editorial, etc. (trade magazine, newspaper, online media) Publisher：Tokyo-igakusha.co.jp
-
ストローマからみた心血管病「ストローマをターゲットとした心血管病の治療」
北村和雄、鶴田敏博
循環器内科 74 125 - 131 2013.8
Language：Japanese Publishing type：Article, review, commentary, editorial, etc. (scientific journal) Publisher：科学評論社
Presentations 【 display / non-display 】
-
Bystander cardiopulmonary resuscitation by nonfamily is associated with neurologically favorable survival after out-of-hospital cardiac arrest in Miyazaki city district
Tsuruda T, Endo GJ, Kaikita K
第87回日本循環器学会学術集会 2023.3.10
Event date： 2023.3.10 - 2023.3.12
Language：English Presentation type：Poster presentation
-
Cardiac troponin-T is expressed in lung cancer tissues and is associated with pathological severity
Tsuruda T, Hatakeyama K, Asada Y, Kaikita K
第86回日本循環器学会学術集会 2022.3.11
Event date： 2022.3.10 - 2022.3.13
Language：English Presentation type：Oral presentation (general)
-
心血管保護因子としてのオステオプロテゲリン Invited
鶴田敏博、小出雅則、中道裕子、中村美どり、宇田川信之、北村和雄
第62回歯科基礎医学会学術大会 2020.9.11
Event date： 2020.9.11 - 2020.9.13
Language：Japanese Presentation type：Symposium, workshop panel (nominated)
-
ショックを呈した頻脈性心房細動 －確実な一手でバイタル管理－
山村善政、竹内貴哉、黒木建吾、小山彰平、井手口武史、鬼塚久充、鶴田敏博、石川哲憲、北村和雄
第127回 日本循環器学会九州地方会
Event date： 2019.12.7
Language：Japanese Presentation type：Oral presentation (general)
-
Osteoprotegerin is co-localized with versican, and plays a role in maintaining the structural integrity in aorta International conference
Yamashita A, Hatakeyama K, Asada Y, Kitamura K
Scientific Sessions 2019 (Philadelphia) American Heart Association
Event date： 2019.11.16 - 2019.11.18
Language：English Presentation type：Poster presentation
Venue：Philadelphia
Awards 【 display / non-display 】
-
第53回高血圧関連疾患モデル学会会長賞
2017 高血圧関連疾患モデル学会
鶴田敏博
Award type：Award from Japanese society, conference, symposium, etc. Country：Japan
-
第120回日本循環器学会九州地方会トランスレーショナルリサーチセッション優秀賞
2016.6 日本循環器学会九州支部
鶴田敏博
Award type：Award from Japanese society, conference, symposium, etc. Country：Japan
-
Best Poster in the Basic/ Translational Domain ACC Geriatric Cardiology Member Section
2016.4 American College of Cardiology
Tsuruda T
Award type：Award from international society, conference, symposium, etc. Country：United States
-
Best poster award (neurohormones) at European Society of Cardiology Congress
2015.8 European Society of Cardiology
Tsuruda T
Award type：Award from international society, conference, symposium, etc. Country：United Kingdom
-
第7回 Cardiovascular Translational Research Conference Award
2011.1 Cardiovascular Translational Research Conference
鶴田 敏博
Country：Japan
Grant-in-Aid for Scientific Research 【 display / non-display 】
-
ナトリウム利尿ペプチド（NPs）は心肥大を促進しうるか
Grant number：23K07581 2023.04 - 2026.03
独立行政法人日本学術振興会 科学研究費基金 基盤研究（C）
加藤 丈司
Authorship：Coinvestigator(s)
-
Role of Cardiac Troponin-T Expression in Cancer Tissues
Grant number：22K08128 2022.04 - 2025.03
Authorship：Principal investigator
-
心不全・動脈瘤の発症/進展におけるオステオプロテゲリンの関与
2014.04 - 2017.03
科学研究費補助金 基盤研究(C)
Authorship：Principal investigator
心不全・動脈瘤の発症/進展におけるオステオプロテゲリンの関与
-
腹部大動脈瘤の病態解明と細胞内エネルギー制御による内科的治療法の基盤確立
2011.04 - 2014.03
科学研究費補助金 基盤研究(C)
Authorship：Principal investigator
（１） 腹部大動脈瘤壁の炎症基盤をPositron emission tomography-computed tomography (PET-CT)で評価し、瘤壁の組織学的・分子生物学的な解析と併せて、腹部大動脈瘤の発症、進展・破裂の病態・機序を明らかにする。
（２） 瘤壁内の炎症細胞（特にマクロファージ）のエネルギー産生調節（グルコース・トランスポーターの発現・糖代謝機能調節）に着眼した新規内科的治療法開発の基盤を確立する。 -
腹部大動脈瘤の形成におけるマスト細胞の関与
2008.04 - 2011.03
科学研究費補助金 基盤研究(C)
Authorship：Principal investigator
腹部大動脈瘤の形成におけるマスト細胞の関与